Isoniazid-resistant tuberculosis: a cause for concern?

Abstract

The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes. It is estimated, however, that 16.1% of TB disease cases in the former Soviet Union countries and 7.5% of cases outside of these settings have non-multidrug-resistant (MDR) INH resistance. Resistance has been linked to poorer treatment outcomes, post-treatment relapse and death, at least for specific sites of disease. Multiple genetic loci are associated with phenotypic resistance; however, the relationship between genotype and phenotype is complex, and restricts the use of rapid sequencing techniques as part of the diagnostic process to determine the most appropriate treatment regimens for patients. The burden of resistance also influences the usefulness of INH preventive therapy. Despite seven decades of INH use, our knowledge in key areas such as the epidemiology of resistant strains, their clinical consequences, whether tailored treatment regimens are required and the role of INH resistance in fuelling the MDR-TB epidemic is limited. The importance of non-MDR INH resistance needs to be re-evaluated both globally and by national TB control programmes.

Figure 1. Percentage of incident tuberculosis cases with isoniazid resistance but not rifampicin resistance, 1994–2009

World map showing the percentage of incident tuberculosis disease that was isoniazid resistant, but not multidrug resistant, 1994–2009. National level data only, sourced and analysed as per Jenkins et al. Where countries submitted repeated estimates most recent data shown only. White areas did not report national data during the time period in question.